Werewolf Files S-4 for Reverse Merger with Ambros: $150M PIPE, 72% Ambros Ownership, CVR for Legacy Assets
HOWL has more than doubled off its 52-week low of $0.27 on light trading volume (0.1× avg).
Summary
Werewolf filed its S-4 for the reverse merger with Ambros Therapeutics, disclosing full deal terms: $500M Ambros valuation, $150M PIPE, and Werewolf stockholders retaining only ~6.4% of the combined company. A CVR distribution tied to legacy assets and a reverse stock split are also proposed.
Key Events · M&A and Partnerships · HOWL
-
S-4 Filed for Reverse Merger with Ambros
Werewolf filed its formal S-4 registration statement and preliminary proxy statement on September 22, 2026, for the reverse merger with Ambros Therapeutics first announced August 21, 2026. Ambros is valued at $500M, Werewolf at $47.5M, with a $150M concurrent PIPE financing.
-
Massive Dilution for Werewolf Stockholders
Post-merger ownership: pre-merger Werewolf equity holders ~6.4%, pre-merger Ambros equity holders ~72.0%, and PIPE investors ~21.6% (fully diluted, treasury stock method). Werewolf stockholders face severe dilution as Ambros effectively takes control.
-
CVR Distribution for Legacy Assets
Werewolf stockholders will receive one Contingent Value Right (CVR) per share, entitling them to 100% of net proceeds from any monetization of the legacy WTX-124 and WTX-330 INDUKINE programs during the CVR period (up to 3 years post-closing).
-
Reverse Stock Split Proposed
A reverse stock split at a ratio to be determined (range not yet specified) is proposed to increase the per-share price above Nasdaq's $1.00 minimum bid requirement. Werewolf has until January 30, 2027 to regain compliance.
Analysis · HOWL · Life Sciences
Werewolf Therapeutics filed its formal S-4 registration statement and preliminary proxy statement for the reverse merger with Ambros Therapeutics, first announced on August 21, 2026. This filing provides the first complete disclosure of the deal terms: Ambros is valued at $500M, Werewolf at $47.5M, and a concurrent $150M PIPE financing will fund the combined company. Post-merger, Werewolf stockholders will own only ~6.4% of the combined company, while Ambros equity holders will own ~72% and PIPE investors ~21.6%. Werewolf stockholders will receive one Contingent Value Right (CVR) per share, tied to the monetization of the legacy WTX-124 and WTX-330 programs. The deal is expected to close in Q1 2027, subject to stockholder approval of ten proposals including a reverse stock split to regain Nasdaq compliance. This is a transformative event for Werewolf — the company is effectively being acquired by Ambros in a reverse merger, and existing Werewolf stockholders face massive dilution. The filing also confirms the going-concern risk: if the merger fails, Werewolf may pursue dissolution and liquidation.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HOWL was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.7M. The 52-week trading range was $0.27 to $2.38. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.